MedTrace Logo

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 39

Last updated 2015-03-17

No results posted yet for this study

Summary

To evaluate the role of inhaled corticosteroids to suppress nitric oxide gas exchange in stable patients with moderate-to-severe COPD who are current non-smokers and not on oral corticosteroids.

Conditions

Interventions

DRUG

fluticasone 100mcg/ salmeterol 50mcg

inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months

DRUG

fluticasone 250/salmeterol 50

inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide

DRUG

salmeterol

salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide

DRUG

Salmeterol

salmeterol 50mcg bid X 3months

DRUG

salmeterol and fluticasone propionate

salmeterol 50mcg/fluticasone 250mcg by DPI bid

Sponsors & Collaborators

  • Arthur F Gelb MD

    lead INDIV

Principal Investigators

  • Arthur F Gelb, MD · Arthur F Gelb Medical Corporation

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2013-10-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568347 on ClinicalTrials.gov